Humana Inc. (HUM) Stock Price & How to Invest
Last updated November 2026
Short answer
You can invest in Humana (HUM) by buying shares or fractional shares at any major broker, through an ETF that holds it, or as one holding in a thematic basket. Humana is one of the largest Medicare Advantage health insurers in the United States, paired with its growing CenterWell healthcare-services arm, so the thesis rests on aging-population demand, a multi-year margin turnaround, and scale in government health programs. The stock has rebounded strongly, up about 58% in 2026 to roughly $417 as of October 16, helped by a sharp star-ratings recovery. The biggest risk is still the Medicare Advantage business itself: rising medical costs, star ratings that determine CMS bonus payments, and shifting reimbursement and policy can pressure margins and earnings.
HUM stock price
As of 2026-11-16, Humana Inc. (HUM) last closed at $461.25, up 97.0% over the past year. Over the past 52 weeks it has traded between $163.67 and $461.25.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Humana Inc.'s investor relations page. Walnut is informational, not investment advice.
HUM key stats
At $461.25 on November 16, 2026, Humana Inc. (HUM) has a market cap of $55.4B, a P/E of 45.0 on trailing earnings (26.6 on forward earnings) and a dividend yield of 0.77%.
- Market cap
- $55.4B
- P/E (trailing)
- 45.0
- P/E (forward)
- 26.6
- EPS (trailing 12 months)
- $10.25
- Price to book
- 2.9
- Dividend yield
- 0.77%
- Beta
- 0.64
Market cap, P/E and yield are measured at the $461.25 price on November 16, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.
What's new with Humana Inc. (HUM)?
The last two weeks for Humana Inc., as of November 17, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.
- HUM closed at $461.25 on November 16, 2026, up 9.0% over the past five trading days (from $423.22).
- On November 9, 2026, Humana Inc. filed an 8-K with the SEC reporting other events (Item 8.01). Read the 8-K on sec.gov
- On November 6, 2026, Humana Inc. filed its quarterly report (10-Q) with the SEC. Read the 10-Q on sec.gov
- On November 6, 2026, Humana Inc. filed an 8-K with the SEC reporting quarterly results and information shared with investors (Regulation FD) (Item 2.02, Item 7.01). Read the 8-K on sec.gov
- On November 9, 2026, Piper Sandler raised its target to $526.00 from $463.00 (Overweight).
- On November 9, 2026, Guggenheim raised its target to $521.00 from $471.00 (Buy).
- On November 9, 2026, Barclays raised its target to $587.00 from $582.00 (Overweight).
Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.
What does Humana Inc. (HUM) do?
Humana Inc. is a Louisville-based health and well-being company best known as one of the two largest Medicare Advantage insurers in the country, alongside UnitedHealth. Its Insurance segment covered roughly 7.1 million individual and group Medicare Advantage members as of early 2026, plus Medicaid, military (TRICARE), and pharmacy-benefit members. The core economics turn on the medical loss ratio, the share of premium dollars paid out as medical claims, and on CMS star ratings, which determine quality-bonus payments that fund richer plan benefits.
Membership growth has pushed revenue sharply higher: trailing twelve-month revenue reached about $146 billion by mid-2026, with Q2 2026 revenue of about $40.9 billion up roughly 26% year over year. Adjusted EPS of $7.61 in Q2 beat the $7.00 estimate. In October 2026, the scorecard for the 2027 star ratings showed about 95% of Humana's Medicare members in plans rated four stars or better, compared with about 20% a year earlier, a result that drives bonus payments in 2028. The company also plans to drop 37 PPO plans for 2027 as it continues repricing and pruning, and its CenterWell expansion drew a capital commitment from BlackRock.
What's driving Humana Inc. (HUM)?
Demographic tailwind in Medicare Advantage
The US population aged 65 and older keeps growing, and a rising share of seniors choose Medicare Advantage over traditional Medicare. Humana reported about 7.1 million Medicare Advantage members in early 2026, up roughly 22% year over year, and that growth shows up in revenue, which rose about 26% in Q2 2026. This long-run enrollment trend is the central reason the bull case exists.
CenterWell healthcare services
CenterWell combines pharmacy, senior primary care, and home health into a services arm that produced roughly $22.5 billion in revenue in 2025, with CenterWell Pharmacy alone near $13 billion. The strategy is to capture more of the healthcare dollar and coordinate care for Humana's own members, which can both add revenue and help manage medical costs over time. In October 2026, BlackRock capital was lined up to support CenterWell's expansion.
Margin recovery and star-ratings rebound
After a period of elevated medical costs, management is targeting a multi-year margin rebuild, aiming to roughly double Medicare Advantage margin in 2026 and reach a sustainable level near 3% by 2028 through repricing plans, exiting unprofitable markets (including 37 PPO plans for 2027), and operating efficiency. The October 2026 star ratings, with about 95% of members in four-star-or-better plans versus about 20% a year earlier, strengthen the 2028 bonus outlook. Analysts expect adjusted EPS of about $9.16 in 2026 and about $17.09 in 2027.
Scale in government programs
Concentrating on Medicare Advantage, Medicaid, and TRICARE gives Humana scale, data, and provider relationships in government-funded health coverage. That focus removed the lower-margin commercial group business and lets the company specialize, though it also concentrates the model around policy and reimbursement decisions made by federal and state programs.
What are the risks to Humana Inc. (HUM)?
The medical-cost trend is the dominant risk: when seniors use more care than priced for, the medical loss ratio rises and margins compress, which is what drove the earnings pressure of 2024-2025. Margins remain thin, with a trailing operating margin near 3.5% and net margin under 1%. Earnings are also seasonal: consensus calls for an adjusted loss of about $1.00 per share in Q3 2026 and about $7.86 in Q4, as Medicare Advantage costs build through the year. Star ratings are a second lever; the 2027 rebound helps, but ratings are recalculated every year and a slip would reduce CMS quality-bonus payments. Medicare Advantage reimbursement and broader healthcare policy are set by the government and can change rate updates, risk-adjustment rules, or audit intensity. Finally, aggressive membership growth or repricing, such as the 2027 PPO exits, can pressure profitability or cause member attrition if benefits are trimmed too far, and after a roughly 58% rally in 2026 more of the recovery is already priced in.
What is the Humana Inc. (HUM) forecast?
24 analysts publish price targets on HUM, averaging $475.54 as of November 2026, or +3.1% against the $461.25 share price on November 16, 2026. The published targets run from $280.00 to $596.00, a moderate spread, and the ratings split 16 buy, 9 hold, 1 sell. Over the last six months there have been 11 raises and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.
Read the full HUM forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.
Is HUM a buy or a sell?
We give no verdict on Humana Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.
The case for buying. Demographic tailwind in Medicare Advantage. The US population aged 65 and older keeps growing, and a rising share of seniors choose Medicare Advantage over traditional Medicare. The most optimistic published target, $596.00, assumes this works close to its best case.
The case against. The medical-cost trend is the dominant risk: when seniors use more care than priced for, the medical loss ratio rises and margins compress, which is what drove the earnings pressure of 2024-2025. The most pessimistic target, $280.00, is roughly what HUM is worth if this bites instead.
Read the full bull and bear case on HUM, including what would have to change to break either one. Walnut is not an investment adviser.
Has Humana Inc. (HUM) split its stock?
No. Humana Inc. (HUM) has not split its stock in the last 10 years. The statement covers only the window we check, so an older split in the company’s history is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.
How is Humana Inc. (HUM) valued?
Market cap, P/E and dividend yield at today's price are in the HUM key stats above. The business figures below come from Humana Inc.'s reported results as of October 2026 and change when it next reports.
- Revenue (TTM): ~$146 billion
- Revenue growth (Q2 2026, YoY): ~26%
- Operating / net margin (TTM): ~3.5% / ~0.9%
As of October 2026: At about $417, Humana trades near 39x trailing earnings, a figure inflated by depressed recent profits, and about 24x analysts' 2027 estimate, which assumes earnings nearly double next year as the margin recovery and star-ratings bonuses arrive. The stock trades at only about 0.34x sales, typical of a thin-margin insurer. Q3 2026 results are scheduled for November 6, with consensus calling for a seasonal loss of about $1.00 per share on revenue near $40.9 billion.
Who competes with Humana Inc. (HUM)?
Large diversified managed care
UnitedHealth Group (UNH), the largest Medicare Advantage insurer, which pairs its insurance arm with Optum's services and pharmacy businesses in a model similar to Humana plus CenterWell.
Integrated insurer-pharmacy
CVS Health (CVS), which owns Aetna and a large pharmacy and PBM footprint and competes directly in Medicare Advantage.
Blue-affiliated and commercial-heavy insurers
Elevance Health (ELV), formerly Anthem, with a broad commercial, Medicaid, and growing Medicare presence.
Diversified health-services insurer
The Cigna Group (CI), strong in pharmacy services via Evernorth and commercial coverage, with a smaller Medicare Advantage footprint than Humana.
What stocks are similar to Humana Inc. (HUM)?
Other names that sit close to HUM: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.
How to invest in Humana Inc. (HUM)
There are three common ways to get HUM exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so HUM sits alongside other stocks that express the same thesis.
Walnut takes the portfolio route. Describe a thesis where HUM fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.
The bottom line on Humana Inc. (HUM)
If you believe an aging US population keeps driving Medicare Advantage enrollment, that Humana can rebuild its margins back toward its targeted levels, and that CenterWell's pharmacy, primary-care, and home-health businesses add durable value, then HUM is a way to express that view. October 2026 brought a major data point for the bull case, with about 95% of members projected in four-star-or-better plans, up from about 20% a year earlier. The counterweight is that profitability hinges on the medical-cost trend, star ratings, and government reimbursement, all of which are outside the company's full control, and the stock has already rallied about 56% over a year. How it fits depends on your own goals, time horizon, and how much exposure you already have to healthcare and managed care.
More on Humana Inc. (HUM)
Whether HUM is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is HUM a buy or a sell?, and where the stock could go from here in the HUM stock forecast.
For income investors, whether HUM pays a dividend and how the payout looks is covered in does HUM pay a dividend? And to weigh HUM against a peer, read the full side-by-side comparisons: HUM vs UNH and HUM vs CVS.
Wondering how HUM fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Humana Inc.
Ask Walnut's AI anything about HUM and see how it fits what you own.
FAQ
Is HUM a good stock to buy right now?
+
That depends on your goals and risk tolerance, and this is not advice. The bull case is the aging-population tailwind, Humana's Medicare Advantage scale, CenterWell, a star-ratings rebound to about 95% of members in four-star-or-better plans, and a margin recovery toward roughly 3% by 2028. The bear case is that medical costs and reimbursement changes could keep margins thin, and the stock is already up about 58% in 2026. Weigh both and your own situation.
What does Humana do?
+
Humana is a health insurer focused on government programs, especially Medicare Advantage, where it covered about 7.1 million members in early 2026. It also serves Medicaid and military TRICARE members. Through its CenterWell arm it operates pharmacy, senior primary care, and home-health businesses, aiming to coordinate care and capture more of the healthcare dollar for its own members.
Does HUM pay a dividend?
+
Yes. Humana pays a quarterly dividend of about $0.885 per share, about $3.54 a year, which works out to roughly a 0.8% yield at a share price near $417 in October 2026. The yield has fallen as the stock rallied. The company has paid and generally raised its dividend for many consecutive years and also repurchases stock, though dividend policy can change with earnings and is set by the board.
Why did Humana stock drop?
+
Humana fell sharply from 2024 into 2025 as Medicare Advantage medical costs ran higher than priced, compressing margins and forcing earnings cuts. A downgrade in CMS star ratings reduced future quality-bonus payments, adding pressure. The stock hit a 52-week low near $163, then recovered to about $417 by mid-October 2026 as earnings beat estimates and the 2027 star ratings rebounded strongly.
How can I buy Humana stock?
+
You can buy HUM through any major brokerage by searching the ticker and placing a market or limit order, and many brokers support fractional shares so you can invest a set dollar amount. You can also gain exposure indirectly through healthcare or managed-care ETFs that hold Humana, or hold it as one position inside a thematic basket alongside related companies.
What is a medical loss ratio and why does it matter for HUM?
+
The medical loss ratio (MLR) is the share of premium dollars an insurer pays out as medical claims. A lower MLR generally means more is left for administration and profit. Humana guided to an MLR around 92.75% for 2026, and with a trailing operating margin near 3.5%, even small swings in member medical usage can meaningfully move margins and earnings, making it a closely watched metric.
How do Medicare Advantage star ratings affect Humana?
+
CMS rates Medicare Advantage plans on a star scale, and higher ratings earn quality-bonus payments that fund richer member benefits and aid retention. Humana's ratings slipped for 2026, creating an earnings headwind. The 2027 ratings released in October 2026 reversed that, with about 95% of members projected in plans rated four stars or better versus about 20% a year earlier; those ratings drive bonus payments in 2028.
What is CenterWell?
+
CenterWell is Humana's healthcare-services brand, spanning pharmacy, senior-focused primary care clinics, and home health. It generated about $22.5 billion in segment revenue in 2025, with CenterWell Pharmacy alone near $13 billion. The strategy is to deliver and coordinate care for Humana's members, which can add revenue and help manage the medical costs that drive insurance margins. In October 2026, BlackRock capital was arranged to support its expansion.
How did Humana do in its latest quarter?
+
In Q2 2026 (quarter ended June 30), Humana reported revenue of about $40.9 billion, up roughly 26% year over year, and adjusted EPS of $7.61 against a $7.00 estimate. GAAP net income was about $694 million. Q3 2026 results are due November 6, 2026, where consensus expects a seasonal adjusted loss of about $1.00 per share.
How has HUM stock performed in 2026?
+
Strongly. As of October 16, 2026, HUM closed near $417, up about 58% year to date and about 56% over one year, with a 52-week range of roughly $163 to $457. Analysts' mean price target is about $465 across 24 analysts.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Humana Inc.'s investor relations page or your broker before making investment decisions.